I am a
Home I AM A Search Login

Papers of the Week


Papers: 30 Apr 2022 - 6 May 2022


Pharmacology/Drug Development


2022 May 03


Am J Clin Dermatol

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.

Authors

Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, Seo S J, Khokhar FA, Vakil J, Xiao J, Marco A R, Levit NA, O'Malley JT, Shabbir A
Am J Clin Dermatol. 2022 May 03.
PMID: 35503163.

Abstract

Moderate-to-severe atopic dermatitis (AD) often requires long-term management with systemic therapies.